How Do Incentive-Based Formularies Influence Drug Selection And Spending For Hypertension?
- 1 January 2004
- journal article
- Published by Health Affairs (Project Hope) in Health Affairs
- Vol. 23 (1) , 227-236
- https://doi.org/10.1377/hlthaff.23.1.227
Abstract
This study examined the association between incentive-based formularies and antihypertensive drug selection and spending. We compared the use of drugs from five drug classes by the number of tiers and copayment differentials. We found that raising copayments within a single-tier formulary system had a relatively modest impact on use of antihypertensives, compared with raising them in multi-tier systems. Likelihood of using ACE inhibitors and angiotensin II receptor blockers was lower among two-tier plans with generic/brand differentials of dollars 10 relative to flat-copayment plans. Incentive formularies were associated with lower total antihypertensive spending by plans, but enrollees paid more out of pocket.Keywords
This publication has 6 references indexed in Scilit:
- Reference Pricing For Drugs: Is It Compatible With U.S. Health Care?Health Affairs, 2003
- The Efficient Use Of Pharmaceuticals: Does Europe Have Any Lessons For A Medicare Drug Benefit?Health Affairs, 2003
- Employer Drug Benefit Plans and Spending on Prescription DrugsJAMA, 2002
- Outcomes of Reference Pricing for Angiotensin-Converting–Enzyme InhibitorsNew England Journal of Medicine, 2002
- Thee-tier Copay Systems and Consumer-centric CareJournal of Managed Care Pharmacy, 2000
- The Effect of Increased Prescription Drug Cost-Sharing on Medical Care Utilization and Expenses of Elderly Health Maintenance Organization MembersMedical Care, 1997